The effect of hypoxia on PD-L1 expression in bladder cancer

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1471-2407

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: The effect of hypoxia on PD-L1 expression in bladder cancer ; volume:21 ; number:1 ; day:25 ; month:11 ; year:2021 ; pages:1-11 ; date:12.2021
BMC cancer ; 21, Heft 1 (25.11.2021), 1-11, 12.2021

Creator: Smith, Vicky
Mukherjee, Debayan
Lunj, Sapna
Choudhury, Ananya
Hoskin, Peter
West, Catharine
Illidge, Tim

Contributor: SpringerLink (Online service)

DOI: 10.1186/s12885-021-09009-7

URN: urn:nbn:de:101:1-2022020118013202855177

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:23 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Smith, Vicky
Mukherjee, Debayan
Lunj, Sapna
Choudhury, Ananya
Hoskin, Peter
West, Catharine
Illidge, Tim
SpringerLink (Online service)

Other Objects (12)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial

Hochschulschrift

Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation

Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer

Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer

Hochschulschrift

Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial

Hochschulschrift

Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation

Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer

Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer

Hochschulschrift

Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial

Hochschulschrift

Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation

Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer

Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer

Hochschulschrift

Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

The effect of hypoxia on PD-L1 expression in bladder cancer

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial

Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation

Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation

Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer

Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer

Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial

Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation

Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation

Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer

Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer

Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial

Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation

Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation

Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer

Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer

Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Related objects

Reset password